BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 20521898)

  • 1. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
    Chung YH; Song BC; Lee GC; Shin JW; Ryu SH; Jung SA; Yoo K; Lee HC; Lee YS; Suh DJ
    Eur J Gastroenterol Hepatol; 2003 May; 15(5):489-93. PubMed ID: 12702905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
    Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
    J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
    Bernardi M; Biselli M; Gramenzi A
    Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
    Sonneveld MJ; Zoutendijk R; Janssen HL
    J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of quantitative hepatitis B virus DNA levels in serum and liver biopsy samples of chronic hepatitis B patients].
    Rüzgar M; Cetin Akhan S; Vahaboğlu H
    Mikrobiyol Bul; 2008 Apr; 42(2):283-91. PubMed ID: 18697426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.
    Su TH; Hsu CS; Chen CL; Liu CH; Huang YW; Tseng TC; Liu CJ; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2010; 15(8):1133-9. PubMed ID: 21149920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of antiviral resistance in patients with chronic hepatitis B.
    Locarnini S; Hatzakis A; Heathcote J; Keeffe EB; Liang TJ; Mutimer D; Pawlotsky JM; Zoulim F
    Antivir Ther; 2004 Oct; 9(5):679-93. PubMed ID: 15535405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg.
    Lee JH; Kim SJ; Ahn SH; Lee J; Park Y; Kim HS
    J Clin Pathol; 2010 Nov; 63(11):1027-31. PubMed ID: 20870658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of chronic hepatitis B: 2009 update.
    Morgan M; Keeffe EB
    Minerva Gastroenterol Dietol; 2009 Mar; 55(1):5-22. PubMed ID: 19212304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of chronic hepatitis B virus infection: a new era of disease control.
    Farrell GC; Teoh NC
    Intern Med J; 2006 Feb; 36(2):100-13. PubMed ID: 16472264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B.
    Moucari R; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():122-8. PubMed ID: 21205149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.
    Lian M; Zhou X; Wei L; Qiu S; Zhou T; Li L; Gu X; Luo M; Zheng X
    Virol J; 2007 Sep; 4():93. PubMed ID: 17892580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients.
    Bell SJ; Lau A; Thompson A; Watson KJ; Demediuk B; Shaw G; Chen RY; Ayres A; Yuen L; Bartholomeusz A; Locarnini SA; Desmond PV
    J Clin Virol; 2005 Feb; 32(2):122-7. PubMed ID: 15653414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.